Drug Interactions between cyclobenzaprine and Loratadine Reditab
This report displays the potential drug interactions for the following 2 drugs:
- Loratadine Reditab (loratadine)
Interactions between your drugs
No interactions were found between cyclobenzaprine and Loratadine Reditab. This does not necessarily mean no interactions exist. Always consult your healthcare provider.
- Cyclobenzaprine is in the drug class skeletal muscle relaxants.
- Cyclobenzaprine is used to treat the following conditions:
A total of 69 drugs are known to interact with Loratadine Reditab.
- Loratadine reditab is in the drug class antihistamines.
- Loratadine reditab is used to treat the following conditions:
Drug and food interactions
Applies to: cyclobenzaprine
Alcohol can increase the nervous system side effects of cyclobenzaprine such as dizziness, drowsiness, and difficulty concentrating. Some people may also experience impairment in thinking and judgment. You should avoid or limit the use of alcohol while being treated with cyclobenzaprine. Do not use more than the recommended dose of cyclobenzaprine, and avoid activities requiring mental alertness such as driving or operating hazardous machinery until you know how the medication affects you. Talk to your doctor or pharmacist if you have any questions or concerns.
Applies to: Loratadine Reditab (loratadine)
Consumer information for this minor interaction is not currently available. Some minor drug interactions may not be clinically relevant in all patients. Minor drug interactions do not usually cause harm or require a change in therapy. However, your healthcare provider can determine if adjustments to your medications are needed.
For clinical details see professional interaction data.
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
|Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
|No interaction information available.|